Artigo Acesso aberto Revisado por pares

Prognostic Value of the Tumor Size in Resectable Colorectal Cancer with Different Primary Locations: A Retrospective Study with the Propensity Score Matching

2019; Ivyspring International Publisher; Volume: 10; Issue: 2 Linguagem: Inglês

10.7150/jca.26882

ISSN

1837-9664

Autores

Xiao Li, Bang An, Jincai Ma, Bo He, Jianni Qi, Wenwen Wang, Chengyong Qin, Qi Zhao,

Tópico(s)

Genetic factors in colorectal cancer

Resumo

Objective: To investigate the prognostic value of the tumor size in colorectal cancer (CRC) patients with different primary tumor locations. Patients and methods:We retrospectively recruited 3971 stage I-III CRC patients with curative resection.The propensity score matching technique was conducted to reduce the selection bias, producing a propensity score matched cohort of 1347 pairs of patients based on the tumor size (≤4 cm and >4 cm groups).Kaplan-Meier survival analyses and univariate and multivariate analyses were used to compare the overall survival (OS), cancer-specific survival (CSS) and disease-free survival (DFS) between the two groups.Subgroup analyses which were stratified by primary tumor locations and several other baseline variables were also performed for conformation.Results: In the propensity score matched cohort, the Kaplan-Meier survival curves revealed that patients with a tumor size less than 4 cm had similar OS, CSS and DFS, compared to patients with a tumor size greater than 4 cm.While in multivariate analyses, the smaller tumor size was an independent risk factor for CSS (HR, 1.275; 95% CI, 1.006-1.616;P=0.045).Subgroup analyses based on primary tumor locations further suggested that the smaller tumor size was significantly associated with worse OS (HR, 2.455; 95% CI, 1.297-4.649;P=0.006) and CSS (HR, 2.493; 95% CI, 1.202-5.174;P=0.014) in patients with right-side colon cancers (RCC).Conclusions: Our propensity matching score study indicated that the smaller tumor size was an independent risk factor for CSS in patients with stage I-III CRC, and for OS and CSS in patients with RCC.

Referência(s)